PT-112: Phase I started

SciClone began an open-label, Taiwanese Phase I trial to evaluate IV PT-112 plus docetaxel every 3 weeks in about 75 patients. The dose-escalation Phase I portion will test PT-112 at a starting dose of 50 mg/m 2 and will enroll patients with solid tumors and the Phase II portion will enroll patients with non-small cell lung cancer (NSCLC). ...